- Coral Laboratories is a pharmaceutical formulator - it takes active drug ingredients and turns them into finished medicines ready for a patient or a farmer. Incorporated in 1981, the company has spent four decades building a single-minded manufacturing business that now spans human, veterinary and aqua-health products, sold across India and exported to international markets. Its recurring approach is to pair a deliberately wide product range with a steadily expanding in-house manufacturing base, so that it can serve many therapeutic needs from its own plants rather than relying on third parties.
Business segments
A single engine - pharmaceutical formulations - that makes finished-dose medicines for humans and animals, sold domestically and exported, with all production run from two company-owned plants.
1. Pharmaceutical formulations: the company's only business
Coral makes finished medicines in dosage forms - ointments, liquids, tablets - and sells them to domestic and export customers, with every rupee of revenue coming from this one activity.
- Two plants, one expanding fast - manufacturing happens at Daman and at Dehradun, where the ointment unit's capacity was recently doubled from 180,000 kgs to 360,000 kgs, funded by bank overdraft and internal cash, to meet growing captive demand and export orders.
- Exports are the growth engine - export revenue has climbed from roughly ₹50 crore in FY23 to nearly ₹95 crore in FY25, handled by a dedicated business-development team that manages everything from enquiry to logistics and regulatory paperwork.
- A deliberately wide product net - the company's scope covers antibiotics, steroids, vitamins, vaccines, herbal products, veterinary medicine, aqua medicine, feed additives and more, which spreads risk across many therapeutic categories and customer types.
- Technology as the moat - management points to a "strong technological base" as the foundation that lets the company compete in a crowded market, backed by internal control systems that are continuously upgraded.
- Standalone by design - Coral has no holding company, no subsidiaries and no joint ventures, so all manufacturing capability, customer relationships and cash flows sit inside one listed entity.
Group structure and partners
Coral is a standalone listed company with no group entities - every asset, customer contract and banking relationship sits directly on its own balance sheet.
- Listed only on BSE - the company's shares trade under scrip code 524506, with a tripartite agreement in place with NSDL, CDSL and its registrar, MUFG Intime India, for dematerialised settlement.
- Single banking relationship - HDFC Bank is the company's banker, providing the overdraft facility that partly funded the Dehradun expansion.
- No complex capital structure - Coral has never issued convertible securities, stock options, sweat equity or warrants, and carries no outstanding GDRs or ADRs.
- No public deposits - the company has not accepted or renewed any deposits from the public, keeping its funding simple and internal.